Continue to site >
Trending ETFs

Name

As of 11/04/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

VanEck Biotech ETF

BBH | ETF

$170.41

$452 M

0.42%

$0.71

0.35%

Vitals

YTD Return

3.3%

1 yr return

13.1%

3 Yr Avg Return

-4.5%

5 Yr Avg Return

6.1%

Net Assets

$452 M

Holdings in Top 10

67.3%

52 WEEK LOW AND HIGH

$170.8
$146.82
$182.72

Expenses

OPERATING FEES

Expense Ratio 0.35%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 41.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund


Name

As of 11/04/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

VanEck Biotech ETF

BBH | ETF

$170.41

$452 M

0.42%

$0.71

0.35%

BBH - Profile

Distributions

  • YTD Total Return 3.3%
  • 3 Yr Annualized Total Return -4.5%
  • 5 Yr Annualized Total Return 6.1%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.23%
DIVIDENDS
  • Dividend Yield 0.4%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    VanEck Biotech ETF
  • Fund Family Name
    VANECKFUND
  • Inception Date
    Dec 20, 2011
  • Shares Outstanding
    2996503
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Peter Liao

Fund Description

The Fund normally invests at least 80% of its total assets in securities that comprise the Fund’s benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. To be initially eligible for the Biotech Index, companies must generate at least 50% of their revenues from biotechnology. Biotechnology includes companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment (excluding pharmacies). Of the largest 50 stocks in the biotechnology industry by full market capitalization, the top 25 by free-float market capitalization (i.e., includes only shares that are readily available for trading in the market) and three month average daily trading volume are included in the Biotech Index. As of December 31, 2023, the Biotech Index included 23 securities of companies with a market capitalization range of between
approximately $4.9 billion and $154.1 billion and a weighted average market capitalization of $69.1 billion. These amounts are subject to change. The Fund’s 80% investment policy is non-fundamental and may be changed without shareholder approval upon 60 days’ prior written notice to shareholders.
The Fund, using a “passive” or indexing investment approach, attempts to approximate the investment performance of the Biotech Index by investing in a portfolio of securities that generally replicates the Biotech Index. Unlike many investment companies that try to “beat” the performance of a benchmark index, the Fund does not try to “beat” the Biotech Index and does not seek temporary defensive positions that are inconsistent with its investment objective of seeking to replicate the Biotech Index.
The Fund is classified as a non-diversified fund under the Investment Company Act of 1940, as amended (the “Investment Company Act of 1940”) and, therefore, may invest a greater percentage of its assets in a particular issuer. The Fund may concentrate its investments in a particular industry or group of industries to the extent that the Biotech Index concentrates in an industry or group of industries. As of September 30, 2023, each of the biotechnology and life sciences tools & services industries represented a significant portion of the Fund.
Read More

BBH - Performance

Return Ranking - Trailing

Period BBH Return Category Return Low Category Return High Rank in Category (%)
YTD 3.3% -26.9% 24.4% 88.05%
1 Yr 13.1% -7.8% 49.2% 90.57%
3 Yr -4.5%* -32.5% 9.5% 81.58%
5 Yr 6.1%* -4.9% 13.7% 78.77%
10 Yr 4.4%* 0.1% 13.3% 88.29%

* Annualized

Return Ranking - Calendar

Period BBH Return Category Return Low Category Return High Rank in Category (%)
2023 3.5% -12.6% 19.0% 40.25%
2022 -15.6% -53.9% 3.2% 75.00%
2021 11.6% -39.6% 24.2% 17.76%
2020 21.7% -13.6% 178.2% 24.16%
2019 25.9% 3.8% 63.8% 21.80%

Total Return Ranking - Trailing

Period BBH Return Category Return Low Category Return High Rank in Category (%)
YTD 3.3% -26.9% 24.4% 88.05%
1 Yr 13.1% -7.8% 49.2% 90.57%
3 Yr -4.5%* -32.5% 9.5% 81.58%
5 Yr 6.1%* -4.9% 13.7% 78.77%
10 Yr 4.4%* 0.1% 13.3% 88.29%

* Annualized

Total Return Ranking - Calendar

Period BBH Return Category Return Low Category Return High Rank in Category (%)
2023 3.9% -12.6% 19.0% 52.83%
2022 -15.2% -53.9% 3.7% 79.61%
2021 11.8% -33.9% 26.0% 34.21%
2020 22.1% -0.7% 180.6% 51.68%
2019 26.3% 4.6% 63.8% 45.86%

BBH - Holdings

Concentration Analysis

BBH Category Low Category High BBH % Rank
Net Assets 452 M 6.87 M 47.2 B 57.86%
Number of Holdings 27 26 430 98.74%
Net Assets in Top 10 292 M 2.12 M 22.1 B 55.97%
Weighting of Top 10 67.28% 18.4% 79.7% 4.40%

Top 10 Holdings

  1. Amgen Inc 15.42%
  2. Vertex Pharmaceuticals Inc 9.95%
  3. Regeneron Pharmaceuticals Inc 8.27%
  4. Gilead Sciences Inc 7.24%
  5. Argenx SE 5.04%
  6. IQVIA Holdings Inc 4.84%
  7. Biogen Inc 4.51%
  8. ICON PLC 4.40%
  9. Moderna Inc 4.02%
  10. Illumina Inc 3.60%

Asset Allocation

Weighting Return Low Return High BBH % Rank
Stocks
99.98% 87.34% 106.13% 5.03%
Cash
0.10% 0.00% 33.01% 91.82%
Preferred Stocks
0.00% 0.00% 7.86% 61.64%
Other
0.00% -22.99% 23.24% 63.52%
Convertible Bonds
0.00% 0.00% 0.37% 46.10%
Bonds
0.00% 0.00% 12.39% 59.12%

Stock Sector Breakdown

Weighting Return Low Return High BBH % Rank
Healthcare
100.00% 59.26% 100.00% 24.03%
Utilities
0.00% 0.00% 0.00% 42.21%
Technology
0.00% 0.00% 22.69% 46.10%
Real Estate
0.00% 0.00% 5.89% 46.10%
Industrials
0.00% 0.00% 7.02% 46.10%
Financial Services
0.00% 0.00% 1.60% 59.09%
Energy
0.00% 0.00% 0.00% 42.21%
Communication Services
0.00% 0.00% 9.11% 45.45%
Consumer Defense
0.00% 0.00% 25.73% 49.35%
Consumer Cyclical
0.00% 0.00% 1.92% 46.10%
Basic Materials
0.00% 0.00% 7.16% 61.69%

Stock Geographic Breakdown

Weighting Return Low Return High BBH % Rank
US
99.98% 66.06% 104.41% 4.40%
Non US
0.00% 0.00% 28.87% 82.39%

BBH - Expenses

Operational Fees

BBH Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.35% 0.08% 4.48% 93.71%
Management Fee 0.35% 0.03% 1.25% 6.29%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

BBH Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

BBH Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

BBH Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 41.00% 0.00% 238.00% 42.96%

BBH - Distributions

Dividend Yield Analysis

BBH Category Low Category High BBH % Rank
Dividend Yield 0.42% 0.00% 6.24% 29.56%

Dividend Distribution Analysis

BBH Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual Quarterly Annual

Net Income Ratio Analysis

BBH Category Low Category High BBH % Rank
Net Income Ratio 0.23% -2.54% 1.85% 24.34%

Capital Gain Distribution Analysis

BBH Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

BBH - Fund Manager Analysis

Managers

Peter Liao


Start Date

Tenure

Tenure Rank

Dec 20, 2011

10.45

10.5%

Mr. Liao has been employed by Van Eck Associates Corporation as an analyst since the summer of 2004 and has been a portfolio manager since 2006. Mr. Liao graduated from New York University in 2004 with a Bachelor of Arts in Economics and Mathematics. He is a CFA charterholder.

Guo Hua (Jason) Jin


Start Date

Tenure

Tenure Rank

Feb 01, 2018

4.33

4.3%

Guo Hua (Jason) Jin has been employed by Van Eck Associates Corporation as an analyst since January 2007 and has been a portfolio manager since 2018. Mr. Jin graduated from the State University of New York at Buffalo in 2004 with a Bachelor of Science degree in Business Administration with a concentration in Financial Analysis.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.88 0.25